Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Apr;35(4):780–782. doi: 10.1128/aac.35.4.780

Effect of clindamycin on pneumonia from reactivation of Toxoplasma gondii infection in mice.

G A Filice 1, C Pomeroy 1
PMCID: PMC245100  PMID: 2069389

Abstract

Clindamycin was used to treat the reactivation of a chronic Toxoplasma gondii infection in mice. Clindamycin reduced mortality by 44% when used prophylactically (P less than 0.001) but appeared to be less effective when used to treat clinically apparent reactivation. Further studies should be conducted to establish the efficacy of clindamycin for the treatment of toxoplasmosis in humans.

Full text

PDF
780

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araujo F. G., Guptill D. R., Remington J. S. In vivo activity of piritrexim [corrected] against Toxoplasma gondii. J Infect Dis. 1987 Nov;156(5):828–830. doi: 10.1093/infdis/156.5.828. [DOI] [PubMed] [Google Scholar]
  2. Araujo F. G., Huskinson J., Remington J. S. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother. 1991 Feb;35(2):293–299. doi: 10.1128/aac.35.2.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Araujo F. G., Remington J. S. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother. 1974 Jun;5(6):647–651. doi: 10.1128/aac.5.6.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Catterall J. R., Hofflin J. M., Remington J. S. Pulmonary toxoplasmosis. Am Rev Respir Dis. 1986 Apr;133(4):704–705. doi: 10.1164/arrd.1986.133.4.704. [DOI] [PubMed] [Google Scholar]
  5. Chang H. R., Jefford C. W., Pechère J. C. In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii. Antimicrob Agents Chemother. 1989 Oct;33(10):1748–1752. doi: 10.1128/aac.33.10.1748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chang H. R., Pechère J. C. In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother. 1988 Apr;32(4):524–529. doi: 10.1128/aac.32.4.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dannemann B. R., Israelski D. M., Remington J. S. Treatment of toxoplasmic encephalitis with intravenous clindamycin. Arch Intern Med. 1988 Nov;148(11):2477–2482. [PubMed] [Google Scholar]
  8. Hamadto H. H., Rashed S. M., Marii N. E., Sobhy M. M., el-Ridi A. M., el-Fakahany A. F. The effect of some drugs on acute toxoplasmosis in mice. J Egypt Soc Parasitol. 1989 Dec;19(2):523–526. [PubMed] [Google Scholar]
  9. Harper J. S., 3rd, London W. T., Sever J. L. Five drug regimens for treatment of acute toxoplasmosis in squirrel monkeys. Am J Trop Med Hyg. 1985 Jan;34(1):50–57. doi: 10.4269/ajtmh.1985.34.50. [DOI] [PubMed] [Google Scholar]
  10. Harris C., Salgo M. P., Tanowitz H. B., Wittner M. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J Infect Dis. 1988 Jan;157(1):14–22. doi: 10.1093/infdis/157.1.14. [DOI] [PubMed] [Google Scholar]
  11. Hofflin J. M., Remington J. S. Clindamycin in a murine model of toxoplasmic encephalitis. Antimicrob Agents Chemother. 1987 Apr;31(4):492–496. doi: 10.1128/aac.31.4.492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hofflin J. M., Remington J. S. In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii. Antimicrob Agents Chemother. 1987 Feb;31(2):346–348. doi: 10.1128/aac.31.2.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Luft B. J., Brooks R. G., Conley F. K., McCabe R. E., Remington J. S. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA. 1984 Aug 17;252(7):913–917. [PubMed] [Google Scholar]
  14. Luft B. J. Potent in vivo activity of arprinocid, a purine analogue, against murine toxoplasmosis. J Infect Dis. 1986 Oct;154(4):692–694. doi: 10.1093/infdis/154.4.692. [DOI] [PubMed] [Google Scholar]
  15. Mack D. G., McLeod R. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother. 1984 Jul;26(1):26–30. doi: 10.1128/aac.26.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McMaster P. R., Powers K. G., Finerty J. F., Lunde M. N. The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice. Am J Trop Med Hyg. 1973 Jan;22(1):14–17. doi: 10.4269/ajtmh.1973.22.14. [DOI] [PubMed] [Google Scholar]
  17. Pomeroy C., Kline S., Jordan M. C., Filice G. A. Reactivation of Toxoplasma gondii by cytomegalovirus disease in mice: antimicrobial activities of macrophages. J Infect Dis. 1989 Aug;160(2):305–311. doi: 10.1093/infdis/160.2.305. [DOI] [PubMed] [Google Scholar]
  18. Rolston K. V., Hoy J. Role of clindamycin in the treatment of central nervous system toxoplasmosis. Am J Med. 1987 Sep;83(3):551–554. doi: 10.1016/0002-9343(87)90769-8. [DOI] [PubMed] [Google Scholar]
  19. Thiermann E., Apt W., Atias A., Lorca M., Olguín J. A comparative study of some combined treatment regimens in acute toxoplasmosis in mice. Am J Trop Med Hyg. 1978 Jul;27(4):747–750. doi: 10.4269/ajtmh.1978.27.747. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES